Q3 2017 EPS Estimates for Catabasis Pharmaceuticals, Inc. Lifted by Analyst (CATB)
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) – Equities researchers at Oppenheimer Holdings raised their Q3 2017 earnings estimates for Catabasis Pharmaceuticals in a report issued on Monday. Oppenheimer Holdings analyst H. Singh now forecasts that the biotechnology company will earn ($0.35) per share for the quarter, up from their previous estimate of ($0.40). Oppenheimer Holdings currently has a “Outperform” rating and a $4.00 target price on the stock. Oppenheimer Holdings also issued estimates for Catabasis Pharmaceuticals’ Q4 2017 earnings at ($0.36) EPS, FY2017 earnings at ($1.48) EPS, FY2018 earnings at ($1.17) EPS, FY2019 earnings at ($1.83) EPS and FY2020 earnings at ($0.69) EPS.
Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.08.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/16/q3-2017-eps-estimates-for-catabasis-pharmaceuticals-inc-lifted-by-analyst-catb.html.
A number of other equities research analysts have also issued reports on CATB. Wedbush reissued an “ourperform” rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. HC Wainwright upped their target price on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Monday. Finally, Zacks Investment Research cut shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.50.
Catabasis Pharmaceuticals (CATB) opened at 1.19 on Wednesday. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $7.89. The company’s market cap is $26.74 million. The firm’s 50-day moving average is $1.27 and its 200 day moving average is $1.39.
Large investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Catabasis Pharmaceuticals during the first quarter valued at $106,000. Oppenheimer & Co. Inc. acquired a new stake in Catabasis Pharmaceuticals during the first quarter worth approximately $144,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Catabasis Pharmaceuticals during the second quarter worth approximately $271,000. 32.93% of the stock is owned by hedge funds and other institutional investors.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.